The article talks about how changing the rules about cannabis (a plant some people use as a drug) might help or hurt different groups of people who deal with it. Some people sell cannabis illegally and might make more money now that the rules are less strict. Other companies that sell cannabis legally might also do better because they can save money on taxes. The article tries to figure out which groups will benefit the most from this change in the law. Read from source...

- The title of the article is misleading and sensationalized, as it implies that only three entities are the biggest winners from rescheduling cannabis, while ignoring the many other stakeholders and factors involved in this complex issue. A more accurate title could be "How Rescheduling Cannabis May Impact The Legal And Illicit Markets And Selected Cannabis Companies".
- The article relies heavily on anecdotal evidence and opinions from industry insiders, without providing any solid data or statistics to support the claims made. For example, the statement "President Joe Biden's support of the administration's decision to reschedule cannabis from Schedule I to Schedule III is likely to result in considerable financial benefits for large, legal cannabis businesses" is not backed up by any sources or analysis. A more rigorous and balanced approach would be to present both the pros and cons of rescheduling cannabis, as well as the potential implications for different segments of the market.
- The article shows a clear bias towards Curaleaf Holdings and Trulieve Cannabis, two of the largest multistate operators in the U.S., by highlighting their positive outlooks and growth prospects without mentioning any of their challenges or risks. A more objective and comprehensive evaluation would also consider other cannabis companies, such as small businesses, vertical integrators, ancillary firms, and international players, as well as the impact of rescheduling on consumers, patients, regulators, law enforcement, and society at large.
- The article uses emotional language and hyperbole to convey its message, such as "the illicit market will get a huge boost by removing the punishments associated with getting caught dealing or transporting a Schedule 1 drug" and "look for the illicit market to boom across America". These statements are exaggerated and speculative, and do not reflect the reality or complexity of the situation. A more rational and nuanced approach would acknowledge the potential benefits and drawbacks of rescheduling cannabis for both the legal and illicit markets, as well as the factors that may influence their development and performance.
- The article ends with a call to action for readers to subscribe to Benzinga Pro, a paid service that provides trading tools and news, without disclosing any conflict of interest or sponsorship. This is an inappropriate and unethical way to promote a product, and undermines the credibility and objectivity of the article. A more transparent and professional approach would disclose any affiliations or partnerships with the companies or organizations mentioned in the article, and provide a balanced and informative summary of

The rescheduling of cannabis from Schedule I to Schedule III has significant implications for various stakeholders in the industry, including legal operators, illicit market participants, consumers, regulators, and law enforcement agencies. Here are some possible investment recommendations and risks associated with this change:

1. The Illicit Market: As mentioned above, the removal of punishments associated with dealing or transporting a Schedule I drug will likely boost the illicit market's demand and supply. This could result in higher profits for illegal growers, distributors, and sellers, as well as increased competition and price pressures for legal operators. However, the long-term sustainability of this growth may be threatened by potential enforcement actions, taxation, and regulation efforts from state and federal authorities. Investors interested in the illicit market should consider these factors when evaluating the risks and rewards of investing in this segment.

2. Curaleaf Holdings (OTC:CURLF): As one of the largest and most diversified cannabis operators in the U.S., Curaleaf stands to benefit from the rescheduling of cannabis, especially in terms of reduced tax liabilities, increased access to capital, and improved operating efficiency. The company operates in 19 states and has a presence in both medical and adult-use markets, which gives it exposure to various customer segments and growth opportunities. Curaleaf also has a strong balance sheet, with over $600 million in cash and no long-term debt, which should enable it to pursue strategic acquisitions and expansion initiatives. However, the company still faces regulatory uncertainties at the federal level, as well as competition from other large players like Trulieve and Green Thumb Industries (OTC:GTBIF). Investors interested in Curaleaf should monitor these factors when making their investment decisions.

3. Trulieve Cannabis (OTC:TCNNF): As another major player in the cannabis industry, Trulieve has a dominant market position in Florida and Pennsylvania, with over 140 dispensaries across both states. The company also operates in Arizona, California, Connecticut, Massachusetts, and Nevada, giving it exposure to diverse customer bases and growth opportunities. Like Curaleaf, Trulieve is expected to benefit from the reduced tax burden and increased access to capital resulting from the rescheduling of cannabis. The company also has a strong cash position of over $200 million and no long-term debt, which should enable it to fund its expansion plans. However, Trulieve faces similar regulatory and competitive challenges as Curaleaf